Philip Mease, MD, discusses the FDA's label expansion for guselkumab's inhibition of structural joint damage in psoriatic arthritis.
Philip J. Mease, MD
Advertisement
Philip J. Mease, MD, is a rheumatologist based in Seattle, Washington and director of the rheumatology research division at Providence Swedish Medical Center.
Articles by Philip J. Mease, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Third RP1 BLA Resubmission for Advanced Melanoma
2
Skin Cancer by the Numbers: A Closer Look at the Latest Data
3
Social Media Mythbusters: Overnight Sheet Masks
4
Evommune's EVO756 Misses Primary End Point in Phase 2b CSU Trial, Development Continues in AD and Migraine
5